Psilocybin for neuralgia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 12 Dec 2024: Trial registered, NCT06731335
  2. 5 Mar 2025: Trial started, NCT06731335

The trials

NCT06731335: Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN

State
Under way
Phase
Phase 2
People
30 planned
Started
5 Mar 2025
Primary completion
Aug 2026
Arms
Intervention Arm with Psilocybin
Results
None posted
  1. 12 Dec 2024: Trial registered
  2. 5 Mar 2025: Trial started

NCT07251491: Psilocybin to Treat Depression in Spinal Cord Injury

State
Under way
Phase
Phase 1 and Phase 2
People
30 planned
Started
6 Aug 2026
Primary completion
1 Mar 2028
Arms
Psilocybin Low Dose, Psilocybin Medium Dose, Psilocybin High Dose
Results
None posted
  1. 26 Nov 2025: Trial registered
  2. 6 Aug 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as High Dose Psilocybin, Low Dose Psilocybin, Medium Dose Psilocybin, Psilocybin (0.25mg/kg), Psilocybin (Usona Institute), Psilocybin (drug), Psilocybin 100 mcg/kg, Psilocybin 25 mg, Psilocybin 25 mg per os, Psilocybin 25mg, Psilocybin assisted therapy, Psilocybin first, Psilocybin plus Visual Healing Set and Setting, Psilocybin therapy, psilocybin 25 mg sod.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.